Alternative Data for Healthcare Investors (Part I): A Primer on Real-World Data
There is an ever-expanding supply of alternative data sources that can be utilised by pharma, biotech, and medtech investors. In this piece, we turn our attention away from “traditional” clinical trial data towards Real-World Data (RWD). Namely, data that is generated in real-world medical settings. In the first of a series of healthcare-focused Neudata intelligence articles, we provide a primer on the RWD landscape, including 1) an introduction to healthcare data and how RWD is defined, 2) the different types and sources of RWD, and 3) regional differences in the collection and availability of RWD.
BEYOND COMMERCIALISATION: PUTTING REAL-WORLD DATA INTO CONTEXT
For pharma, biotech, and medtech companies, the journey from product discovery to commercialisation is a long and difficult process (it takes at least 10 years, on average, to bring a drug to market),1 and the outcome at each stage of this process can have a significant impact on a company’s financial success. As discussed in our previous piece on using alternative data to evaluate pharmaceutical pipelines, data relating to clinical development success rates (in this case,